From: Clinical significance of serum CA125 in diffuse malignant mesothelioma
No. | Median OS (months) | Survival at months (%) | Hazard ratio | P value | ||||
---|---|---|---|---|---|---|---|---|
6 | 12 | 18 | 24 | |||||
Age | 1.881 | 0.147 | ||||||
≤60 years | 28 | 13 ± 10.2 | 74.6 | 52.4 | 47.6 | 47.6 | ||
>60 years | 13 | 5 ± 2.2 | 34.6 | 26.0 | 26.0 | 26.0 | ||
Gender | 1.850 | 0.157 | ||||||
Male | 28 | 43 ± 25.1 | 67.9 | 52.4 | 52.4 | 52.4 | ||
Female | 13 | 6 ± 2.8 | 45.1 | 22.6 | 11.3 | 11.3 | ||
Performance status (ECOG) | 3.013 | 0.018 | ||||||
0–1 | 33 | 13 ± 15.4 | 68.3 | 53.0 | 48.9 | 48.9 | ||
2 | 8 | 2 ± 1.4 | 37.5 | 12.5 | 12.5 | 12.5 | ||
Primary tumor location | 0.236 | 0.003 | ||||||
Pleura | 23 | 6 ± 2.1 | 51.5 | 22.9 | 22.9 | 22.9 | ||
Pritoneum | 18 | – | 88.9 | 68.8 | 61.9 | 61.9 | ||
Histological subtype | 2.281 | 0.006 | ||||||
Epithelial | 14 | 43 ± 27.9 | 85.7 | 85.7 | 85.7 | 85.7 | ||
Sarcomatoid | 1 | 13 | 1 | 1 | 0 | 0 | ||
Unspecified | 26 | 6 ± 1.5 | 56.7 | 20.4 | 20.4 | 20.4 | ||
Surgery | 0.363 | 0.069 | ||||||
CRS | 11 | – | 90.0 | 70.0 | 60.0 | 60.0 | ||
nCRS | 30 | 7 ± 2.0 | 52.1 | 35.8 | 35.8 | 35.8 | ||
Systemic chemotherapy | 0.340 | 0.015 | ||||||
Yes | 23 | 43 ± 31.8 | 77.1 | 60.9 | 55.4 | 55.4 | ||
No | 18 | 4 ± 3.0 | 43.8 | 25.0 | 25.0 | 25.0 | ||
Local chemotherapy | 0.486 | 0.156 | ||||||
Yes | 13 | – | 61.5 | 61.5 | 61.5 | 61.5 | ||
No | 28 | 9 ± 2.1 | 61.6 | 37.3 | 32.0 | 32.0 | ||
Stage of disease | 11.495 | 0.017 | ||||||
III | 10 | – | 88.9 | 88.9 | 88.9 | 88.9 | ||
IV | 31 | 7 ± 2.5 | 52.1 | 31.0 | 26.6 | 26.6 | ||
Baseline of CA125 | 2.214 | 0.045 | ||||||
≤280 U/ml | 28 | 43 ± 23.4 | 70.6 | 57.7 | 52.9 | 52.9 | ||
>280 U/ml | 13 | 5 ± 1.7 | 44.9 | 17.9 | 17.9 | 17.9 |